Amphastar Pharmaceuticals (AMPH) Depreciation & Amortization (CF) (2013 - 2026)

Amphastar Pharmaceuticals' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $8.1 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 9.62% year-over-year to $8.1 million in Q1 2026; TTM through Mar 2026 was $32.4 million, a 5.1% decrease from a year earlier, with the FY2025 full-year figure at $31.6 million, up 12.03% from the prior year.
• Depreciation & Amortization (CF) steadied at $8.1 million in Q1 2026 per AMPH's latest filing, from $8.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $9.8 million in Q3 2024 and bottomed at $2.7 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $7.9 million (2025), against an average of $6.7 million.
• Biggest YoY gain for Depreciation & Amortization (CF) was 215.9% in 2024; the steepest drop was 24.84% in 2024.
• Year by year, Depreciation & Amortization (CF) stood at $3.4 million in 2022, then soared by 180.86% to $9.7 million in 2023, then declined by 24.84% to $7.3 million in 2024, then grew by 11.22% to $8.1 million in 2025, then advanced by 0.09% to $8.1 million in 2026.
• Per Business Quant, the three latest AMPH Depreciation & Amortization (CF) figures stand at $8.1 million (Q1 2026), $8.1 million (Q4 2025), and $7.9 million (Q3 2025).